NewAmsterdam Pharma Company N.V — Cash Flow (NASDAQ:NAMS) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities —141.22 M158.56 M147.78 M 147.78 M Cash from investing activities —24 K62.85 M174.92 M 174.92 M Cash from financing activities —8.91 M659.51 M29.52 M 29.52 M Free cash flow —141.19 M157.89 M147.54 M 147.54 M

Notizie

Cantor Fitzgerald conferma il rating Overweight sul titolo NewAmsterdam Pharma

Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight

Guggenheim alza il target sul titolo NewAmsterdam Pharma per i tempi del lancio UE

Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing

Gli EPS di NewAmsterdam Pharma hanno mancato le aspettative per 0,23$, il fatturato appena sotto le previsioni

NewAmsterdam Pharma earnings missed by $0.23, revenue fell short of estimates

NewAmsterdam prevede decisione EMA sul farmaco per il colesterolo nella seconda metà del 2026

NewAmsterdam expects EMA decision on cholesterol drug in second half 2026

Leerink Partners alza il target di prezzo delle azioni NewAmsterdam Pharma a $55

NewAmsterdam Pharma stock price target raised to $55 by Leerink Partners

Piper Sandler evidenzia i nomi biotech commerciali da possedere nel 2026

Piper Sandler highlights commercial biotech names to own in 2026